R5 | X4 | p value | |
---|---|---|---|
N patients | 68 (58%) | 50 (42%) | |
Male gender (N,%) | 52 (76%) | 36 (72%) | 0.6 |
Age (years, mean ± SD) | 51.2 ± 5.6 | 50.6 ± 5.9 | 0.1 |
Foreign nationality (N,%) | 1 (1.5%) | 1 (2.0%) | 0.8 |
HIV-1 non B subtype (N,%) | 15 (22%) | 7 (14%) | 0.3 |
Risk factor (N,%) | |||
- parenteral | 44 (65%) | 27 (54%) | |
- sexual | 23 (34%) | 21 (42%) | 0.4 |
ART duration (years; median, IQR) | 13 (9–16) | 14 (10–16) | 0.5 |
- NRTIs | 13 (9–16) | 14 (10–16) | 0.6 |
- NNRTIs | 4 (1–7) | 4 (2–6) | 1.0 |
- PIs | 7 (5–9) | 6 (5–12) | 0.5 |
Past use of mono- or bi-therapy (N,%) | 43 (63%) | 35 (70%) | 0.8 |
Previous AIDS events (N,%) | 7 (10%) | 10 (20%) | 0.2 |
Serious non-AIDS events (N,%) | 19 (39%) | 7 (14%) | 0.07 |
HBsAg pos (N,%) | 9 (13%) | 4 (8%) | 0.1 |
Anti-HCV pos (N,%) | 51 (75%) | 30 (60%) | 0.1 |
pVL (log10 cp/ml;median, IQR) | 3.2 (3.2-4.8) | 4.1 (3.2-8.9) | 0.1 |
Aviremic pts (N,%) | 53 (78%) | 36 (72%) | |
CD4+ cell count (median, IQR) | |||
- absolute (n/mmc) | 658 (219–185) | 558 (109–1219) | 0.1 |
- percentage (%) | 31 (24–53) | 28 (11–52) | 0.1 |
Nadir CD4+ cell count | |||
- absolute (median n/mmc;, IQR) | 137 (90–616) | 87 (27–382) | 0.005 |
- percentage (%) | 11 (7–27) | 8 (2–32) | 0.01 |